Compare ITRM & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | NAII |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 21.2M |
| IPO Year | 2018 | 1987 |
| Metric | ITRM | NAII |
|---|---|---|
| Price | $0.35 | $3.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 998.7K | 17.1K |
| Earning Date | 02-06-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $390,000.00 | ★ $134,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $193.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.00 |
| 52 Week Low | $0.26 | $2.57 |
| 52 Week High | $2.10 | $4.40 |
| Indicator | ITRM | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 69.27 |
| Support Level | $0.26 | $3.14 |
| Resistance Level | $0.37 | $3.55 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 50.18 | 96.97 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.